Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
Add more filters










Publication year range
1.
Cancer Res ; 61(1): 206-14, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11196163

ABSTRACT

Recombinant avian poxviruses [fowlpox and canarypox (ALVAC)], restricted for replication in nonavian cell substrates and expressing granulocyte/macrophage-colony stimulating factor (avipox-GM-CSF), were evaluated for their ability to enrich an immunization site with antigen-presenting cells (APCs) and, in turn, function as biological vaccine adjuvants. Avipox-GM-CSF administered as a single s.c. injection significantly enhanced the percentage and absolute number of APCs in the regional lymph nodes that drain the injection site. Both the magnitude and duration of the cellular and phenotypic increases within the lymph nodes induced by the avipox-GM-CSF viruses were significantly (P < 0.05) greater than those measured in mice treated with four daily injections of recombinant GM-CSF protein. Temporal studies revealed that the APC enrichment of regional lymph nodes was sustained for 21-28 days after injection of the recombinant avipox virus expressing GM-CSF and, moreover, three injections of the recombinant virus could be given without any appreciable loss of in vivo bioactivity. Mice expressing human carcinoembryonic antigen (CEA) as a transgene (CEA.Tg) developed CEA-specific humoral and cell-mediated immunity after being immunized with avipox-CEA. The coadministration of recombinant avipox viruses expressing CEA and GM-CSF significantly enhanced CEA-specific host immunity with an accompanying immunotherapeutic response in tumor-bearing CEA.Tg mice. The optimal use of avipox-GM-CSF, in terms of dose and dose schedule, especially when used with different immunogens, remains to be determined. Nonetheless, the present findings demonstrate: (a) the effective delivery of GM-CSF to an immunization site using a recombinant avian poxvirus; (b) the compatibility of delivering an antigen and GM-CSF in replication-defective viruses to enhance antigen-specific immunity; and (c) the combined use of recombinant avipox viruses expressing CEA and GM-CSF to generate antitumor immunity directed at a self tumor antigen.


Subject(s)
Antigen-Presenting Cells/immunology , Cancer Vaccines/immunology , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Lymph Nodes/immunology , Adjuvants, Immunologic/genetics , Adjuvants, Immunologic/pharmacology , Animals , Antibodies, Neoplasm/biosynthesis , Antibodies, Neoplasm/blood , Avipoxvirus/genetics , Cancer Vaccines/genetics , Carcinoembryonic Antigen/genetics , Carcinoembryonic Antigen/immunology , Chick Embryo , Epitopes, T-Lymphocyte/immunology , Female , Genetic Vectors/genetics , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Humans , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Lymph Nodes/cytology , Lymphocyte Activation/immunology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neoplasms, Experimental/immunology , Neoplasms, Experimental/therapy , Recombinant Proteins , T-Lymphocytes/immunology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology
2.
Proc Natl Acad Sci U S A ; 98(4): 1781-6, 2001 Feb 13.
Article in English | MEDLINE | ID: mdl-11172028

ABSTRACT

The HIV-1 regulatory proteins Rev and Tat are expressed early in the virus life cycle and thus may be important targets for the immune control of HIV-1-infection and for effective vaccines. However, the extent to which these proteins are targeted in natural HIV-1 infection as well as precise epitopes targeted by human cytotoxic T lymphocytes (CTL) remain to be defined. In the present study, 57 HIV-1-infected individuals were screened for responses against Tat and Rev by using overlapping peptides spanning the entire Tat and Rev proteins. CD8+ T cell responses against Tat and Rev were found in up to 19 and 37% of HIV-1-infected individuals, respectively, indicating that these regulatory proteins are important targets for HIV-1-specific CTL. Despite the small size of these proteins, multiple CTL epitopes were identified in each. These data indicate that Tat and Rev are frequently targeted by CTL in natural HIV-1 infection and may be important targets for HIV vaccines.


Subject(s)
Gene Products, rev/immunology , Gene Products, tat/immunology , HIV Infections/immunology , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , CD8-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/immunology , HIV Infections/blood , Humans , Longitudinal Studies , Peptides/immunology , rev Gene Products, Human Immunodeficiency Virus , tat Gene Products, Human Immunodeficiency Virus
3.
Proc Natl Acad Sci U S A ; 97(20): 10917-22, 2000 Sep 26.
Article in English | MEDLINE | ID: mdl-11005863

ABSTRACT

NY-ESO-1 elicits frequent antibody responses in cancer patients, accompanied by strong CD8(+) T cell responses against HLA-A2-restricted epitopes. To broaden the range of cancer patients who can be assessed for immunity to NY-ESO-1, a general method was devised to detect T cell reactivity independent of prior characterization of epitopes. A recombinant adenoviral vector encoding the full cDNA sequence of NY-ESO-1 was used to transduce CD8-depleted peripheral blood lymphocytes as antigen-presenting cells. These modified antigen-presenting cells were then used to restimulate memory effector cells against NY-ESO-1 from the peripheral blood of cancer patients. Specific CD8(+) T cells thus sensitized were assayed on autologous B cell targets infected with a recombinant vaccinia virus encoding NY-ESO-1. Strong polyclonal responses were observed against NY-ESO-1 in antibody-positive patients, regardless of their HLA profile. Because the vectors do not cross-react immunologically, only responses to NY-ESO-1 were detected. The approach described here allows monitoring of CD8(+) T cell responses to NY-ESO-1 in the context of various HLA alleles and has led to the definition of NY-ESO-1 peptides presented by HLA-Cw3 and HLA-Cw6 molecules.


Subject(s)
Antigen Presentation , Antigens, Neoplasm/immunology , CD8-Positive T-Lymphocytes/immunology , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology , Membrane Proteins , Proteins/immunology , Alleles , Cytotoxicity, Immunologic , Gene Transfer Techniques , Genetic Vectors , Humans , Proteins/genetics , Vaccinia virus
4.
Clin Cancer Res ; 6(5): 1632-8, 2000 May.
Article in English | MEDLINE | ID: mdl-10815880

ABSTRACT

A recombinant vaccinia virus encoding human prostate-specific antigen (rV-PSA) was administered as three consecutive monthly doses to 33 men with rising PSA levels after radical prostatectomy, radiation therapy, both, or metastatic disease at presentation. Dose levels were 2.65 x 10(6), 2.65 x 10(7), and 2.65 x 10(8) plaque forming units. Ten patients who received the highest dose also received 250 microg/m2 granulocyte-macrophage colony-stimulating factor (GM-CSF) as an immunostimulatory adjunct. No patient experienced any virus-related effects beyond grade I cutaneous toxicity. Pustule formation and/or erythema occurred after the first dose in all 27 men who received > or =2.65 x 10(7) plaque forming units. GM-CSF administration was associated with fevers and myalgias of grade 2 or lower in 9 of 10 patients. PSA levels in 14 of 33 men treated with rV-PSA with or without GM-CSF were stable for at least 6 months after primary immunization. Nine patients remained stable for 11-25 months; six of these remain progression free with stable PSA levels. Immunological studies demonstrated a specific T-cell response to PSA-3, a 9-mer peptide derived from PSA. rV-PSA is safe and can elicit clinical and immune responses, and certain patients remain without evidence of clinical progression for up to 21 months or longer.


Subject(s)
Cancer Vaccines/therapeutic use , Prostate-Specific Antigen/immunology , Prostatic Neoplasms/prevention & control , Vaccinia virus/genetics , Adult , Aged , Antibodies/blood , Antibodies/drug effects , Cancer Vaccines/adverse effects , Cancer Vaccines/genetics , DNA, Recombinant/administration & dosage , DNA, Recombinant/immunology , Dose-Response Relationship, Drug , Fever/chemically induced , Humans , Male , Middle Aged , Prostate-Specific Antigen/blood , Prostate-Specific Antigen/genetics , Prostatic Neoplasms/immunology , Tachycardia/chemically induced , Treatment Outcome
5.
J Immunol ; 164(2): 934-43, 2000 Jan 15.
Article in English | MEDLINE | ID: mdl-10623842

ABSTRACT

Host immune responses to SIV infection in sooty mangabeys are likely to be an important determinant of how such nonhuman primate species maintain asymptomatic lentivirus infection. We have previously described two patterns of asymptomatic SIV infection in sooty mangabeys: low viral loads with vigorous SIV-specific CTL activity in SIVmac239-infected sooty mangabeys, and high viral loads with generally weak or absent SIV-specific CTL activity in naturally infected sooty mangabeys. To define the specificity of the CTL response in SIV-infected mangabeys, we characterized CTL epitopes in two naturally infected and three SIVmac239-infected sooty mangabeys. Compared with that in SIVmac239-infected mangabeys, the yield of SIV-specific CTL clones was significantly lower in naturally infected sooty mangabeys. All CTL clones were phenotypically CD3+ CD8+, and lysis was MHC restricted. Seven SIV CTL epitopes were identified in five sooty mangabeys: one in Gag and three each in Nef and Envelope (Env). The CTL epitopes mapped to conserved regions in the SIV genome and were immunodominant. Several similar or identical CTL epitopes were recognized by both naturally infected and SIVmac239-infected mangabeys that shared class I MHC alleles. To our knowledge, this is the first report of SIV-specific CTL epitopes in sooty mangabeys. Longitudinal studies of viral load and sequence variation in CTL epitopes may provide useful information on the role of CTL in control or persistence of SIV infection in sooty mangabeys.


Subject(s)
Epitopes, T-Lymphocyte/isolation & purification , Monkey Diseases/immunology , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Animals , Cell Line, Transformed , Cell Separation , Cercocebus atys , Clone Cells , Gene Products, env/immunology , Gene Products, gag/immunology , Gene Products, nef/immunology , Histocompatibility Antigens Class I/biosynthesis , Histocompatibility Antigens Class I/genetics , Immunodominant Epitopes/isolation & purification , Immunophenotyping , Molecular Sequence Data , Monkey Diseases/pathology , Monkey Diseases/virology , Simian Acquired Immunodeficiency Syndrome/pathology , Simian Acquired Immunodeficiency Syndrome/virology , T-Lymphocytes, Cytotoxic/pathology
6.
Nat Med ; 5(5): 526-34, 1999 May.
Article in English | MEDLINE | ID: mdl-10229229

ABSTRACT

Eight different protocols were compared for their ability to raise protection against immunodeficiency virus challenges in rhesus macaques. The most promising containment of challenge infections was achieved by intradermal DNA priming followed by recombinant fowl pox virus booster immunizations. This containment did not require neutralizing antibody and was active for a series of challenges ending with a highly virulent virus with a primary isolate envelope heterologous to the immunizing strain.


Subject(s)
Lentivirus Infections/immunology , Lentivirus Infections/prevention & control , Vaccination , Vaccines, DNA/therapeutic use , Viral Vaccines/therapeutic use , Animals , Antibodies, Viral/blood , Fowlpox virus/genetics , Injections, Intradermal , Macaca , Neutralization Tests , RNA, Viral/blood , T-Lymphocytes, Cytotoxic
7.
Vaccine ; 17(7-8): 893-903, 1999 Feb 26.
Article in English | MEDLINE | ID: mdl-10067696

ABSTRACT

Several recombinant vaccinia viruses are currently being evaluated to induce antigen-specific immunity to a variety of infectious disease agents and tumor associated antigens. T-cell costimulation is extremely important in enhancing T-cell responses, and recombinant vaccines have now been shown to be effective vectors to express a range of these molecules. Both combination vaccines (an admixture of a recombinant vaccinia virus expressing a specific target antigen and a recombinant vaccinia virus expressing a costimulatory molecule) and dual-gene vaccines expressing both transgenes on the same vector have been shown capable of effectively enhancing antigen-specific responses via T-cell costimulation. In this report, we compare for the first time the use of both types of approaches to enhance antigen-specific T-cell responses, and we demonstrate the importance of route of vaccine administration and vaccine dose in attaining optimal T-cell responses. These studies should have direct bearing on the design of vaccine clinical trials for infectious agents and/or tumor associated antigens, in which T-cell costimulatory molecules will be employed to enhance antigen-specific T-cell responses via the use of either combination or dual-gene vaccinia vaccines.


Subject(s)
Adjuvants, Immunologic/pharmacology , T-Lymphocytes/immunology , Vaccines, DNA/immunology , Vaccines, Synthetic/immunology , Vaccinia virus/immunology , Viral Vaccines/immunology , Adjuvants, Immunologic/genetics , Animals , B7-1 Antigen/genetics , B7-1 Antigen/immunology , Carcinoembryonic Antigen/genetics , Carcinoembryonic Antigen/immunology , Epitopes, T-Lymphocyte/immunology , Female , Immunity, Cellular/immunology , Mice , Mice, Inbred C57BL , Transgenes/immunology , Vaccines, Combined/genetics , Vaccines, Combined/immunology , Vaccines, DNA/genetics , Vaccinia virus/genetics , Viral Vaccines/genetics , Viral Vaccines/pharmacology
8.
AIDS Res Hum Retroviruses ; 14(11): 925-37, 1998 Jul 20.
Article in English | MEDLINE | ID: mdl-9686639

ABSTRACT

A major objective of current HIV-1 vaccination strategies is the induction of HIV-1-specific CD8+ MHC class I-restricted CTL responses, which are suggested to play a pivotal role in viral clearance and protection against HIV-1 disease progression. However, the marked genetic diversity of HIV-1 and existence of distinct viral subtypes or clades could potentially hinder the development of a universally efficacious HIV-1 vaccine. In this study we examined HIV-1 intraclade (B(LAI) versus B(MN)) Env gp160-specific CTL reactivity in recently HIV-1 clade B-infected individuals. We further evaluated the extent of interclade CTL cross-recognition of the divergent A and C Env gp160 subtypes, that are highly prevalent in the global pandemic. Freshly isolated PBMCs were stimulated in vitro with autologous PBMCs infected with recombinant vaccinia vectors expressing HIV-1 env, gag, pol, and nef genes derived from HIV-1 clade B. All 13 of the 19 HIV-1-seropositive subjects who elicited significant clade B Env gp160LAI CD8+ CTL responses also demonstrated comparable levels of CTL cross-reactivity against clade C92BR025 Env gp160. Nine of these individuals also showed extensive interclade CTL cross-recognition of clade A92UG037 Env gp160. Two HLA class I B7 donors had nondetectable intraclade CTL response against B Env gp160MN, while generating significant intraclade B(LAI) and interclade (A and C) Env gp160 CTL cross-reactivity. These observations serve to underscore the central importance of the HLA background of individuals in determining the pattern of immune reactivity to natural HIV-1 infection and presumably vaccines. Five donors studied also demonstrated broad CTL cross-reactivity against clade A92UG037 Gag p55, Pol, and/or Nef antigens. In conclusion, this present study indicates that there is a considerable degree of CD8+ CTL cross-recognition of the highly divergent HIV-1 Env gp160 subtypes during early phases of HIV-1 infection. Such findings suggest that HIV-1 vaccines based on a single clade that can induce extensive cross-clade immunity may demonstrate utility in diverse geographical regions.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , HIV Envelope Protein gp160/immunology , HIV Infections/immunology , HIV-1 , T-Lymphocytes, Cytotoxic/immunology , Cloning, Molecular , Cross Reactions , Female , Gene Products, gag/genetics , Gene Products, gag/immunology , Gene Products, nef/genetics , Gene Products, nef/immunology , Gene Products, pol/genetics , Gene Products, pol/immunology , HIV Antigens/immunology , HIV Seropositivity , Histocompatibility Testing , Humans , Male , Protein Precursors/immunology , Vaccinia virus/genetics , Viral Load , nef Gene Products, Human Immunodeficiency Virus
9.
Ann Surg Oncol ; 5(1): 64-76, 1998.
Article in English | MEDLINE | ID: mdl-9524710

ABSTRACT

BACKGROUND: Dendritic cells (DC) are potent professional antigen-presenting cells that can activate naive T lymphocytes and initiate cellular immune responses. As adjuvants, DC may be useful for enhancing immunogenicity and mediating tumor regression. Endogenous expression of antigen by DC could offer the potential advantage of allowing prolonged constitutive presentation of endogenously processed epitopes and exploitation of multiple restriction elements for the presentation of the same antigen. METHODS: DC were prepared from the peripheral blood of HLA A*0201 patients with metastatic melanoma in the presence of IL-4 (1000 IU/mL) and GMCSF (1000 IU/mL). Recombinant vaccinia and fowlpox viruses encoding the hMART-1 gene were constructed and used to infect DC. The efficiency of infection and expression of the MART-1 antigen were assessed by immunohistochemistry and intracellular FACS analyses. Cytotoxic lymphocytes (CTL) were generated by the stimulation of CD8+ T cells, with DC expressing the recombinant gene. Reactivity of the CTL was determined at weeks 1 and 2 by the amount of IFN-gamma released. RESULTS: DC were infected with recombinant poxviruses and demonstrated specific melanoma antigen expression by immunohistochemistry, immunofluorescence, and intracellular FACS analysis. The expression by DC of MART-1 MAA after viral infection was sufficient to generate CD8+ T lymphocytes that recognized naturally processed epitopes on tumor cells in 10 of 11 patients. CONCLUSIONS: Human DC are receptive to infection by recombinant poxviruses encoding MAA genes and are capable of efficiently processing and presenting these MAA to cytotoxic T cells. The potential advantage of this approach is the ability to present specific antigen independent of the identification of the epitope or the MHC restriction element. This strategy may be useful for the identification of relevant epitopes for a diverse number of HLA alleles and for active immunization in patients.


Subject(s)
Antigens, Neoplasm/therapeutic use , Dendritic Cells/immunology , Melanoma/immunology , Melanoma/therapy , Poxviridae , Skin Neoplasms/immunology , Skin Neoplasms/therapy , T-Lymphocytes, Cytotoxic/immunology , Antigens, Neoplasm/biosynthesis , Cells, Cultured , Genetic Vectors/immunology , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Humans , Interferon-gamma/immunology , Interleukin-4/immunology , Poxviridae/genetics , Poxviridae/immunology , Tumor Cells, Cultured
10.
J Virol ; 71(11): 8615-23, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9343219

ABSTRACT

Despite recent advances in antiviral therapy for human immunodeficiency virus (HIV) infection, successful global intervention will require an effective vaccine. Expanding evidence suggests that cytotoxic T-lymphocyte (CTL) responses will be an important component of such a vaccine. The varying geographic distribution of HIV type 1 (HIV-1) clades, with the relative absence of clade B HIV-1 outside the developed world, is considered a major obstacle to the development of a single efficacious vaccine. An understanding of cross-reactive CTL responses between different HIV-1 clades is crucial in the design of a vaccine which will be broadly immunogenic. In this study, we examined the ability of HIV-1 Gag-, reverse transcriptase-, and Env-specific CTL clones isolated from individuals infected in the United States to recognize non-B clade viral sequences and found that all were cross-reactive with the majority of non-B clade viral sequences tested. We next studied HIV-1-specific CTL responses in African individuals infected with clade A, C, or G virus and evaluated cross-recognition of clade B virus. Of 14 persons evaluated, all demonstrated cross-reactivity with the U.S. clade B viral constructs. We conclude that significant CTL cross-reactivity exists between clade B and non-B epitopes, suggesting that CTL cross-recognition among HIV-1 clades is more widespread than anticipated and that a vaccine based on a single clade may be broadly applicable.


Subject(s)
HIV Antigens/immunology , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Base Sequence , Cross Reactions , Epitope Mapping , Gene Products, gag/immunology , Gene Products, nef/immunology , Gene Products, pol/immunology , Genetics, Population , HIV Core Protein p24/immunology , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp41/immunology , HLA Antigens/immunology , Humans , Immunity, Cellular , Molecular Sequence Data , Senegal , United States , nef Gene Products, Human Immunodeficiency Virus
11.
J Immunother ; 20(1): 38-47, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9101412

ABSTRACT

Tumor-associated antigens have considerable promise not only as diagnostic or prognostic markers but also as targets for active or passive immunotherapy. DF3/MUC1 is a tumor-associated antigen that is overexpressed with an abnormal glycosylation pattern in breast, ovarian, lung, and pancreatic cancers. The major extracellular portion of MUC1 is composed of tandem repeat units of 20 amino acids. Recombinant vaccinia viruses encoding mucin molecules have been constructed by several groups. However, these recombinants have met with limited success in protecting animals from MUC1-expressing tumors because of the vaccinia genome being subject to high-frequency homologous recombination, therefore being unstable in expression of the tandem repeats. In light of these studies, two concurrent strategies were used to improve immune responses to MUC1: a recombinant vaccinia virus was constructed containing a modified "mini" MUC1 gene containing only 10 tandem repeat sequences to minimize vaccinia-mediated rearrangement (designated rV-MUC1); and an admixture was used containing rV-MUC1 and a recombinant vaccinia virus containing the gene for the murine T-cell costimulatory molecule B7-1 (rV-B7). The rV-MUC1 gene product maintained a consistent molecular weight throughout several passages, indicating stability of the inserted gene. Mice inoculated with rV-MUC1 demonstrated MUC1-specific cytolytic responses that were further enhanced by admixture with rV-B7. In a MUC1-expressing pulmonary metastases prevention model, mice inoculated two times with rV-MUC1 were protected from the establishment of metastases. No additive effect on antitumor immunity (> 90% with rV-MUC1 alone) was observed in mice primed with an admixture of rV-MUC1 and rV-B7 and boosted with rV-MUC1. When rV-MUC1 was used to treat established MUC1 positive metastases, however, three administrations of rV-MUC1 were not sufficient to confer antitumor effects. In contrast, when tumor-bearing mice were primed with an admixture of rV-MUC1 and rV-B7, followed by two boosts with rV-MUC1, there was a significant reduction in pulmonary metastases (p = < 0.0001), which correlated to 100% survival. Coexpression of the B7 molecule, although not necessary for the induction of an immune response of sufficient magnitude to prevent MUC1 tumors, was thus essential in a treatment setting.


Subject(s)
Antigens, Neoplasm/genetics , Cancer Vaccines/therapeutic use , Gene Expression Regulation, Viral/physiology , Genes, Viral , Vaccines, Synthetic/therapeutic use , Vaccinia virus/genetics , Animals , B7-1 Antigen/genetics , Cancer Vaccines/genetics , Cytotoxicity Tests, Immunologic , Mice , Neoplasm Metastasis/prevention & control , Recombination, Genetic , Repetitive Sequences, Nucleic Acid , T-Lymphocytes/immunology , Transduction, Genetic , Tumor Cells, Cultured , Vaccines, Synthetic/genetics
12.
Magn Reson Imaging ; 14(6): 639-48, 1996.
Article in English | MEDLINE | ID: mdl-8897368

ABSTRACT

A polysaccharide material, TX-151, has been used together with water, NaCl, and Al powder to create a tissue equivalent gel to make a realistic, inexpensive, conveniently moldable, temporally stable tissue equivalent MRI phantom. Various phantom compositions were studied for variations in gelling time and relaxation times. Gd-DTPA added as a T1 (and T2) modifier and aluminum powder added to decrease T2 permitted phantoms to be made with a range of relaxation times comparable to human tissues. We have used this polysaccharide gel to create breast phantoms for testing breast coils and evaluating different MRI imaging sequences available for diagnosis. The breast phantoms consisted of a layer of Crisco, a good model for adipose tissue, surrounding the TX-151 gel. Some of these phantoms were created with a silicone implant encapsulated in the gel to simulate an augmented breast. More sophisticated phantoms can easily be developed by additions of other materials to this polysaccharide gel.


Subject(s)
Magnetic Resonance Imaging , Phantoms, Imaging , Female , Gels , Humans , Polysaccharides
13.
J Virol ; 69(9): 5838-42, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7637030

ABSTRACT

Lack of disease in long-term nonprogressors with human immunodeficiency virus type 1 (HIV-1) infection was strongly associated with very low copy numbers of HIV-1 DNA and RNA in peripheral blood mononuclear cells and plasma and the presence of high levels of anti-HIV-1 CD8+ memory cytotoxic T lymphocytes specific for Gag, Pol, and Env, compared with levels present in intermediate and advanced progressors. CD8+ memory cytotoxic T lymphocytes may have an important role in controlling HIV-1 replication and preventing disease in long-term nonprogressors.


Subject(s)
Acquired Immunodeficiency Syndrome/physiopathology , HIV Infections/physiopathology , HIV Seropositivity/physiopathology , HIV-1/isolation & purification , Immunologic Memory , T-Lymphocytes, Cytotoxic/immunology , Acquired Immunodeficiency Syndrome/drug therapy , Acquired Immunodeficiency Syndrome/immunology , Adult , Aged , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , DNA, Viral/blood , HIV Infections/drug therapy , HIV Infections/immunology , HIV Seropositivity/drug therapy , HIV Seropositivity/immunology , HIV-1/physiology , Humans , Middle Aged , RNA, Viral/blood
14.
AIDS Res Hum Retroviruses ; 11(7): 777-81, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7546903

ABSTRACT

Three of the five hypervariable domains (V1-V3) of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 have previously been shown to be dispensable for antigenic epitopes recognized by broadly neutralizing monoclonal antibodies. In this study, the influence of the V4 and V5 domains on an epitope recognized by a broadly neutralizing human monoclonal antibody, 1.5e, was investigated. In contrast with the V1, V2, and V3 domains of gp120, the V4 and V5 domains were found to be critical for binding to both CD4 and 1.5e. Our results suggest that V4 and V5 are in structurally less flexible regions of gp120 than V1, V2, and V3 and raises the question of whether variable domains V4 and V5 are also indispensable for other broadly neutralizing antibodies in the same class as 1.5e.


Subject(s)
Epitopes/chemistry , Genetic Variation , HIV Envelope Protein gp120/chemistry , HIV Envelope Protein gp120/genetics , HIV-1/immunology , Protein Conformation , Antibodies, Monoclonal , Antigens, CD/immunology , Base Sequence , Binding Sites, Antibody , CD4 Antigens/immunology , HIV Envelope Protein gp120/immunology , HIV-1/genetics , Humans , Molecular Sequence Data , Mutagenesis, Site-Directed , Neutralization Tests , Oligodeoxyribonucleotides , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Sequence Deletion
15.
AIDS Res Hum Retroviruses ; 10(7): 839-51, 1994 Jul.
Article in English | MEDLINE | ID: mdl-7986589

ABSTRACT

Eighteen rhesus monkeys were vaccinated with recombinant vaccinia viruses expressing SIVmac antigens in 3 separate rounds of experiments. Twelve of the monkeys were primed with a trivalent vaccinia virus recombinant expressing Gag, Pol, and Env polypeptides that can assemble into SIV pseudovirion particles and boosted with SIV particles in adjuvant. Four of the monkeys were primed with different vaccinia virus recombinants expressing env or gag+env followed by SIV particle boosts; two received vaccinia virus recombinants alone (env or env+gag). Despite the induction of vigorous immune responses, 17 of 18 rhesus monkeys became infected on challenge with a low dose of virulent SIVmac. The single protected animal was one of three challenged with homologous cloned SIV exactly matched to the clone used for construction of trivalent vaccinia virus recombinant and particles. Vaccination may have diminished SIV burdens and rates of CD4+ cell declines in some of the animals, but vaccinated/challenge/infected animals eventually developed fatal disease similar to control animals. These results highlight the extreme difficulty in achieving vaccine protection against virulent SIVmac infection even under idealized laboratory conditions.


Subject(s)
SAIDS Vaccines/administration & dosage , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/pathogenicity , Animals , Antibody Formation , Blotting, Western , CD4-Positive T-Lymphocytes/pathology , Immunization, Secondary , Macaca mulatta , Simian Acquired Immunodeficiency Syndrome/immunology , Simian Immunodeficiency Virus/immunology , Trachea/pathology , Trachea/ultrastructure , Vaccination , Virulence
16.
AIDS Res Hum Retroviruses ; 9(2): 129-32, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8384466

ABSTRACT

An effective acquired immunodeficiency syndrome (AIDS) vaccine should be capable of eliciting human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte (CTL) responses. We have explored the use of lentivirus-like particles produced in mammalian cells infected with a recombinant vaccinia virus to immunize for the induction of CTL in the simian immunodeficiency virus (SIV)/rhesus monkey model for AIDS. SIV-like particles in a threonyl-MDP-based adjuvant did not elicit a high frequency of SIV gag-specific effector cells in naive rhesus monkeys. However, immunization with these particles elicited a potent recall CTL response in monkeys previously vaccinated with a recombinant vaccinia-SIV virus. These observations suggest that poxvirus-produced virus-like particles may represent a safe immunogen for use in periodic boosting to maintain viable cell-mediated immunity to the AIDS virus.


Subject(s)
Lentivirus/immunology , Simian Immunodeficiency Virus/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Genes, MHC Class I , Genes, env , Genes, gag , Genes, pol , Immunization , Lentivirus/genetics , Macaca mulatta , Simian Immunodeficiency Virus/genetics , Vaccinia virus/genetics , Vaccinia virus/immunology
19.
J Exp Med ; 174(6): 1593-600, 1991 Dec 01.
Article in English | MEDLINE | ID: mdl-1744586

ABSTRACT

The presence of cytotoxic T lymphocytes (CTL) to the gag antigens of human immunodeficiency virus (HIV) has been described in infected populations. We found that the majority of this immune response as measured in bulk CTL assays of unstimulated peripheral blood mononuclear cells (PBMC) is directed against the p24 component of the p55 gag precursor protein. Using limiting dilution analysis of this effector cell population we confirm that the majority of activated gag-specific CTL circulating in the PBMC of infected hemophilic patients are directed at p24 determinants and are present at frequencies of 1/36,000 to 1/86,000 lymphocytes. By performing in vitro stimulation after limiting dilution, the precursor population of gag-specific CTL are characterized and quantitated. HIV gag-specific CTL precursors are identified at frequencies of 1/1700 to 1/17,000 lymphocytes and are made up of cells with both p17 and p24 specificities. No HIV gag-specific CTL precursor cells are identified in the PBMC of HIV-uninfected individuals. These studies demonstrate that CTL directed at both p17 and p24 determinants make up the cellular immune repertoire in HIV-infected individuals but that only the p24-specific CTL are routinely found in an activated state in the circulation.


Subject(s)
Gene Products, gag/immunology , HIV Antigens/immunology , HIV Core Protein p24/immunology , HIV Infections/immunology , T-Lymphocytes, Cytotoxic/immunology , Viral Proteins , CD8 Antigens/analysis , Cytotoxicity, Immunologic , HIV Seropositivity/immunology , Humans , Protein Precursors/immunology , gag Gene Products, Human Immunodeficiency Virus
20.
J Immunol ; 147(5): 1512-21, 1991 Sep 01.
Article in English | MEDLINE | ID: mdl-1715361

ABSTRACT

CTL directed at the highly conserved HIV-1 gag protein have been described in HIV-1 seropositive persons and may be an important host defense against this retrovirus. Presently only limited data are available regarding the specific epitopes recognized by these CTL. In this study, we have performed a detailed examination of the gag-specific CTL response in three HIV-1 seropositive subjects, using both unstimulated PBMC and cloned CTL. Lysis of gag-expressing targets was found to be mediated by CD3+CD8+ lymphocytes and restricted by class I Ag. Multiple class I Ag were found to restrict gag epitopes in each subject studied, with as many as three of these Ag involved in presenting gag CTL epitopes in a single subject. The majority of gag-specific CTL activity was found to be directed against epitopes in the p24 subunit of the gag protein, with at least seven different HLA class I-restricted CTL p24 epitopes identified in these three subjects. Less CTL activity was directed against p17 subunit of gag and two CTL epitopes were identified in this protein. Although as many as four different epitopes in gag were recognized using CTL from a single subject, none of the epitopes was recognized by CTL from more than one subject. Analysis of gag epitope recognition using cloned CTL demonstrated heterogeneity and specificity not appreciated using unstimulated PBMC. The identification of multiple relatively conserved epitopes in the HIV-1 gag protein and the heterogeneity of CTL responses to this protein may have important implications for vaccine development and our understanding of AIDS pathogenesis.


Subject(s)
Epitopes/analysis , Gene Products, gag/immunology , HIV Antigens/immunology , HIV-1/immunology , Leukocytes, Mononuclear/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Base Sequence , Clone Cells , HLA Antigens/immunology , Humans , Molecular Sequence Data
SELECTION OF CITATIONS
SEARCH DETAIL
...